244 related articles for article (PubMed ID: 31937620)
21. Advances in the management of unresectable or metastatic pancreatic neuroendocrine tumors: chemotherapy, targeted therapy, hormonal treatment, and future directions.
Bilici A
Asian Pac J Cancer Prev; 2015; 16(6):2151-9. PubMed ID: 25824731
[TBL] [Abstract][Full Text] [Related]
22. Animal models and cell lines of pancreatic neuroendocrine tumors.
Babu V; Paul N; Yu R
Pancreas; 2013 Aug; 42(6):912-23. PubMed ID: 23851429
[TBL] [Abstract][Full Text] [Related]
23. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors.
Cho CM
Korean J Gastroenterol; 2019 Mar; 73(3):124-131. PubMed ID: 31013555
[TBL] [Abstract][Full Text] [Related]
24. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
Chiu CW; Nozawa H; Hanahan D
J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
[TBL] [Abstract][Full Text] [Related]
25. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
Chamberlain CE; German MS; Yang K; Wang J; VanBrocklin H; Regan M; Shokat KM; Ducker GS; Kim GE; Hann B; Donner DB; Warren RS; Venook AP; Bergsland EK; Lee D; Wang Y; Nakakura EK
Mol Cancer Ther; 2018 Dec; 17(12):2702-2709. PubMed ID: 30254185
[TBL] [Abstract][Full Text] [Related]
26. Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration.
Greenberg J; Limberg J; Verma A; Kim D; Chen X; Lee YJ; Moore MD; Ullmann TM; Thiesmeyer JW; Loewenstein Z; Chen KJ; Egan CE; Stefanova D; Bareja R; Zarnegar R; Finnerty BM; Scognamiglio T; Du YN; Elemento O; Fahey TJ; Min IM
JCI Insight; 2022 Dec; 7(23):. PubMed ID: 36301668
[TBL] [Abstract][Full Text] [Related]
27. Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.
Nilubol N; Yuan Z; Paciotti GF; Tamarkin L; Sanchez C; Gaskins K; Freedman EM; Cao S; Zhao J; Kingston DGI; Libutti SK; Kebebew E
J Natl Cancer Inst; 2018 Sep; 110(9):1019-1029. PubMed ID: 29481652
[TBL] [Abstract][Full Text] [Related]
28. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
29. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
[TBL] [Abstract][Full Text] [Related]
30. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Chan JA; Kulke MH
Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
[TBL] [Abstract][Full Text] [Related]
31. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
[TBL] [Abstract][Full Text] [Related]
32. Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.
Andersson E; Arvidsson Y; Swärd C; Hofving T; Wängberg B; Kristiansson E; Nilsson O
Mod Pathol; 2016 Jun; 29(6):616-29. PubMed ID: 26965582
[TBL] [Abstract][Full Text] [Related]
33. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
[TBL] [Abstract][Full Text] [Related]
34. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
[TBL] [Abstract][Full Text] [Related]
35. mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.
Orr-Asman MA; Chu Z; Jiang M; Worley M; LaSance K; Koch SE; Carreira VS; Dahche HM; Plas DR; Komurov K; Qi X; Mercer CA; Anthony LB; Rubinstein J; Thomas HE
Mol Cancer Ther; 2017 Nov; 16(11):2432-2441. PubMed ID: 28864682
[TBL] [Abstract][Full Text] [Related]
36. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
Duerr EM; Mizukami Y; Ng A; Xavier RJ; Kikuchi H; Deshpande V; Warshaw AL; Glickman J; Kulke MH; Chung DC
Endocr Relat Cancer; 2008 Mar; 15(1):243-56. PubMed ID: 18310291
[TBL] [Abstract][Full Text] [Related]
37. Single-cell RNA sequencing reveals spatiotemporal heterogeneity and malignant progression in pancreatic neuroendocrine tumor.
Zhou Y; Liu S; Liu C; Yang J; Lin Q; Zheng S; Chen C; Zhou Q; Chen R
Int J Biol Sci; 2021; 17(14):3760-3775. PubMed ID: 34671197
[No Abstract] [Full Text] [Related]
38. Animal models of spontaneous pancreatic neuroendocrine tumors.
Yu R
Mol Cell Endocrinol; 2016 Feb; 421():60-7. PubMed ID: 26261055
[TBL] [Abstract][Full Text] [Related]
39. Angiopoietin-2 promotes disease progression of neuroendocrine tumors.
Detjen KM; Rieke S; Deters A; Schulz P; Rexin A; Vollmer S; Hauff P; Wiedenmann B; Pavel M; Scholz A
Clin Cancer Res; 2010 Jan; 16(2):420-9. PubMed ID: 20068079
[TBL] [Abstract][Full Text] [Related]
40. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
Krug S; Gress TM; Michl P; Rinke A
Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]